Stakeholder FGD Data Capture Matrix										
				Demographic Information					Intro	
ID	Date	Demographic Sheet	Duration	Moderator/ Notetaker initials	# of ppts	Region/ Location	Gender	Role(s)/ Work	Role/Position	DMPA-SC Knowledge/ Use

Guidance Followed - Variation - Impact of 4-month product on guidelines	Reaction to 4-month product intro - Additional Info Needs - Trusted Sources of Info	Nat'l Policy Change Motivation - Steps Needed	Systemic Changes Needed for Intro - Specific Mechanisms - Impact on clinic volume, data & monitoring, logistics and distribution	Ensuring Quality Assurance	Changes needed at: - Provider-level - HS-level

	DMPA-SC					
Challenges/ Barriers to Provision	**Impact of intro on training & supervision - Challenges & solutions**	**Other Provider-level Comms Needed**	**Role of cost in provision - incentives - disincentives**	**Insurmountable Challenges - Suggested Mitigations**	**Provider Pref: 3 or 4-mos?**	**Impact of potentially: - Reduced SE - Quicker RT to Fertility**

		Client-centered Communication Needs				
Predominant Type of Administration - Provider prefs	Client prefs - Impact of longer intervals on client confidence & recall	Perceived acceptability among potential clients - benefits & drawbacks	Anticipated client questions/ concerns	Impact of potentially reduced SE on client prefs	Impact of potentially quicker RT to fertility on client prefs	"Ideal" Target Clients

Impact of different durations on market - Potential <u>PROVIDER</u> confusion + solutions - Issues with forecasting, stocking + solutions	**Impact of different durations on market - Potential <u>CLIENT</u> confusion + solutions**	**Client prefs for 'grace period': 3 months + 4 weeks <u>*OR*</u> 4 months + week**	**Acceptability of 6-month product with <u>PROVIDERS</u> - Potential postives and negatives**

Expanding market of injectable contraceptives				
Acceptability of 6-month product with <u>CLIENTS</u> - Potential postives and negatives	**Likelihood of switching to 6-month - Demand forecast**	**Concern for inability to remove/reverse for 6 mos**	**Optimal inj duration - <u>PROVIDER</u> - Ranked importance of: Administration type, Location of injection, Availability (e.g., clinic-only)**	**Optimal inj duration - <u>CLIENT</u> - Ranked importance of: Administration type, Location of injection, Availability (e.g., clinic-only)**

				Closing
Optimal # of injectables in the Market - [Private sector] Impact on pricing & sales	**Preventing confusion with multiple durations - 3 & 6-month vs 3,4 & 6-month**	**Recommendations for promoting/differentiating 4-month product**	**Recommendations for promoting/differentiating 6-month product**	**Final thoughts/ Questions**